Abstract
Substance use is much more common in individuals with body dysmorphic disorder (BDD) than in the general population (Grant et al., Journal of Clinical Psychiatry 66(3):309–405, 2005). In individuals with muscle dysmorphia (MD), a type of BDD that manifests as a pathological preoccupation with muscularity, the use of various substances that are associated with muscle building, such as anabolic steroids is much more prevalent than in the general population (Pope et al., Body Image 2:395–400, 2005). This chapter will examine the links between MD and such drug use, exploring the literature that has examined this issue, discussing treatment issues, and suggesting future research directions.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
